tipifarnib has been researched along with concanavalin a in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (concanavalin a) | Trials (concanavalin a) | Recent Studies (post-2010) (concanavalin a) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 17,959 | 82 | 1,337 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akahoshi, T; Guo, J; Mizuta, Y; Murata, M; Shirozu, K; Yamaura, K | 1 |
1 other study(ies) available for tipifarnib and concanavalin a
| Article | Year |
|---|---|
The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A.
Topics: Animals; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Concanavalin A; Disease Models, Animal; Hepatitis, Autoimmune; Humans; Interferon-gamma; Liver; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Quinolones | 2020 |